PTC gains on early data for SMA candidate

PTC Therapeutics Inc. (NASDAQ:PTCT) added $2.37 (10%) to $27.03 on Monday after it and partner Roche (SIX:ROG; OTCQX:RHHBY) reported preliminary data from the pivotal Phase II FIREFISH trial of RG7916 (RO7034067) to treat

Read the full 330 word article

User Sign In